Statement: the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame.
Primary_evidence: Outcome Measurement:    Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants   PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first.   Time frame: Baseline up to approximately 34 months Results 1:    Arm/Group Title: Placebo Plus Nab-Paclitaxel   Arm/Group Description: Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 451   Median (95% Confidence Interval)   Unit of Measure: Months  5.49        (5.32 to 5.59) Results 2:    Arm/Group Title: Atezolizumab Plus Nab-Paclitaxel   Arm/Group Description: Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 451   Median (95% Confidence Interval)   Unit of Measure: Months  7.16        (5.59 to 7.46)
Secondary_evidence: Outcome Measurement:    Progression-Free Survival (PFS) at 6 Months (6-month PFS Rate): Proportion of Participants Progression Free at 6 Months   PFS at 6 months was defined as proportion of participants who neither progressed nor died before 6 months. Computed using Kaplan-Meier estimates.   Time frame: From the date of randomization to 6-months on study Results 1:    Arm/Group Title: Ixabepilone 16 mg/m^2   Arm/Group Description: ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest   Overall Number of Participants Analyzed: 85   Measure Type: Number   Unit of Measure: Percentage of Participants  28.6        (18.9 to 38.9) Results 2:    Arm/Group Title: Ixabepilone 40 mg/m^2   Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks   Overall Number of Participants Analyzed: 91   Measure Type: Number   Unit of Measure: Percentage of Participants  42.7        (31.5 to 53.5)